Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Change in Receivables (2016 - 2025)

Apyx Medical (APYX) has disclosed Change in Receivables for 15 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 33.67% year-over-year to $3.9 million, compared with a TTM value of $1.3 million through Dec 2025, down 35.23%, and an annual FY2025 reading of $1.3 million, down 35.23% over the prior year.
  • Change in Receivables was $3.9 million for Q4 2025 at Apyx Medical, up from $1.8 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $3.9 million in Q4 2025 and bottomed at -$3.9 million in Q1 2025.
  • Average Change in Receivables over 5 years is $495500.0, with a median of $529500.0 recorded in 2023.
  • The sharpest move saw Change in Receivables surged 1394.85% in 2021, then crashed 261.86% in 2025.
  • Year by year, Change in Receivables stood at $1.7 million in 2021, then dropped by 21.81% to $1.4 million in 2022, then grew by 1.99% to $1.4 million in 2023, then surged by 110.85% to $2.9 million in 2024, then soared by 33.67% to $3.9 million in 2025.
  • Business Quant data shows Change in Receivables for APYX at $3.9 million in Q4 2025, $1.8 million in Q3 2025, and -$471000.0 in Q2 2025.